AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Davey D and Lina Girl discuss the hottest trends in technology from gaming to life-saving devices to apps that make you ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...